RxDoctor Payments Data

Said Ibrahimi, MD

Neurology · San Jose, CANPI 1376751321

Payments from drug & device makers

$17,485in general payments, 2019–2025

Across 794 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$1K
  • Lilly USA, LLC$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Biogen$963
  • Neurocrine Biosciences, Inc.$821
  • plus $10K from 54 others

What the payments were for

  • Food & beverage$17,439100%
  • Education$460%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)103$2,059
UCB, Inc.48$1,476
Lilly USA, LLC58$1,394
Teva Pharmaceuticals USA, Inc.49$1,083
Biogen46$963
Neurocrine Biosciences, Inc.23$821
SK Life Science, Inc.25$795
Pfizer34$765
Acorda Therapeutics, Inc38$753
Sumitomo Pharma America, Inc.40$688
Neurelis, Inc.22$650
Sunovion Pharmaceuticals Inc.33$610
Eisai Inc.48$508
Johnson & Johnson(2 entities)27$434
Otsuka America Pharmaceutical, Inc.13$413
Kyowa Kirin, Inc.14$329
Aucta Pharmaceuticals, Inc.14$313
GE HealthCare9$220
Biohaven Pharmaceutical Holding Company Ltd.15$210
Biohaven Pharmaceuticals, Inc.20$194
Merz Pharmaceuticals, LLC6$194
Catalyst Pharmaceuticals, Inc.12$186
CSL Behring7$182
Abbott4$174
Axsome Therapeutics, Inc.6$171
AstraZeneca10$152
Octapharma USA, Inc.4$142
Tanabe Pharma America, Inc.6$141
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$124
Impel Pharmaceuticals Inc.6$104
Takeda Pharmaceuticals U.S.A., Inc.4$96
Lundbeck LLC4$93
Alnylam Pharmaceuticals Inc.3$74
Currax Pharmaceuticals LLC4$67
Jazz Pharmaceuticals Inc.3$66
Novartis3$64
Indivior Inc.2$58
Dynasplint Systems Inc.2$57
Amgen2$53
GRT US Holding, Inc.2$51
Amneal Pharmaceuticals LLC2$49
Bristol Myers Squibb2$46
Avanir Pharmaceuticals, Inc.2$37
Braeburn Inc.1$32
Ipsen Biopharmaceuticals, Inc1$32
Averitas Pharma Inc.1$31
Exact Sciences1$29
Corium, LLC1$28
Medtronic1$25
Insulet Corporation1$25
Banner Life Sciences, LLC1$24
Collegium Pharmaceutical, Inc.1$24
Globus Medical1$23
Alkermes, Inc.1$23
Alfasigma USA, Inc.1$23
Grifols USA, LLC1$21
Bausch Health US, LLC1$20
Genentech USA, Inc.1$18
Idorsia Pharmaceuticals US Inc1$17
Adamas Pharmaceuticals, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,485 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$338,711
Medicare patients
309
Services billed
1,264

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate53$73,468
NourianzIstradefylline19$46,892
UbrelvyUbrogepant29$35,455
FycompaPerampanel27$22,683
AptiomEslicarbazepine Acetate17$20,421
NeuproRotigotine22$19,477
VimpatLacosamide11$13,858
Ajovy AutoinjectorFremanezumab-Vfrm17$11,791
Lacosamide42$8,918
Memantine Hcl99$2,618
Carbamazepine ErCarbamazepine28$2,600
Quetiapine Fumarate60$2,109
Levetiracetam84$2,064
Donepezil Hcl259$2,064
Rivastigmine11$2,005

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$765$73,46853 claims
Kyowa Kirin, Inc.Nourianz$329$46,89219 claims
AbbVieUbrelvy$2,059$35,45529 claims
UCB, Inc.Neupro, Vimpat$1,476$33,33633 claims
Eisai Inc.Fycompa$508$22,68327 claims
Sunovion Pharmaceuticals Inc.Aptiom$610$20,42117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in San Jose

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →